NCT06266338View on ClinicalTrials.gov

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Cervix CancerCervical Cancer
Interventions
DRUG

Pembrolizumab

200 mg IV q 3 weeks

DRUG

Lenvatinib

20 mg PO daily

Trial Locations (1)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT06266338 - Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) | Biotech Hunter | Biotech Hunter